z-logo
open-access-imgOpen Access
IFNγ‐producing CD4 + T lymphocytes: the double‐edged swords in tuberculosis
Author(s) -
Kumar Pawan
Publication year - 2017
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1186/s40169-017-0151-8
Subject(s) - pathogenesis , mycobacterium tuberculosis , immune system , immunology , tuberculosis , autophagy , macrophage , immune reconstitution inflammatory syndrome , t cell , interferon , immunity , medicine , virology , biology , virus , apoptosis , antiretroviral therapy , viral load , in vitro , biochemistry , pathology
IFNγ‐producing CD4 + T cells (IFNγ + CD4 + T cells) are the key orchestrators of protective immunity against Mycobacterium tuberculosis ( Mtb ). Primarily, these cells act by enabling Mtb ‐infected macrophages to enforce phagosome‐lysosome fusion, produce reactive nitrogen intermediates (RNIs), and activate autophagy pathways. However, TB is a heterogeneous disease and a host of clinical and experimental findings has also implicated IFNγ + CD4 + T cells in TB pathogenesis. High frequency of IFNγ + CD4 + T cells is the most invariable feature of the active disease. Active TB patients mount a heightened IFNγ + CD4 + T cell response to mycobacterial antigens and demonstrate an IFNγ‐inducible transcriptomic signature. IFNγ + CD4 + T cells have also been shown to mediate TB‐associated immune reconstitution inflammatory syndrome (TB–IRIS) observed in a subset of antiretroviral therapy (ART)‐treated HIV‐ and Mtb ‐coinfected people. The pathological face of IFNγ + CD4 + T cells during mycobacterial infection is further uncovered by studies in the animal model of TB–IRIS and in Mtb ‐infected PD‐1 −/− mice. This manuscript encompasses the evidence supporting the dual role of IFNγ + CD4 + T cells during Mtb infection and sheds light on immune mechanisms involved in protection versus pathogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here